Recent Analysts’ Ratings Updates for Can-Fite BioPharma (CANF)

Several brokerages have updated their recommendations and price targets on shares of Can-Fite BioPharma (NYSE: CANF) in the last few weeks:

• 5/24/2024 – Can-Fite BioPharma is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 5/16/2024 – Can-Fite BioPharma is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 5/9/2024 – Can-Fite BioPharma had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $18.00 price target on the stock.
• 5/8/2024 – Can-Fite BioPharma is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 4/30/2024 – Can-Fite BioPharma is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 4/22/2024 – Can-Fite BioPharma is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 4/14/2024 – Can-Fite BioPharma is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 4/6/2024 – Can-Fite BioPharma is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 3/29/2024 – Can-Fite BioPharma is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.

Can-Fite BioPharma Price Performance

Shares of CANF stock traded up $0.03 during trading hours on Friday, reaching $2.47. 8,476 shares of the company’s stock were exchanged, compared to its average volume of 20,380. The company’s 50 day moving average is $2.17 and its two-hundred day moving average is $2.12. The company has a market cap of $8.74 million, a P/E ratio of -1.38 and a beta of 1.58. Can-Fite BioPharma Ltd. has a 1 year low of $1.81 and a 1 year high of $3.33.

Can-Fite BioPharma (NYSE:CANF) last released its quarterly earnings data on Thursday, March 28th. The company reported ($0.31) EPS for the quarter, missing the consensus estimate of ($0.27) by ($0.04). Can-Fite BioPharma had a negative return on equity of 113.75% and a negative net margin of 1,027.46%. The business had revenue of $0.16 million during the quarter, compared to analysts’ expectations of $0.20 million. As a group, analysts predict that Can-Fite BioPharma Ltd. will post -0.03 EPS for the current fiscal year.

Hedge Funds Weigh In On Can-Fite BioPharma

A hedge fund recently bought a new stake in Can-Fite BioPharma stock. Armistice Capital LLC purchased a new position in shares of Can-Fite BioPharma Ltd. (NYSE:CANF) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 154,363 shares of the company’s stock, valued at approximately $340,000. Armistice Capital LLC owned approximately 4.36% of Can-Fite BioPharma as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 21.00% of the company’s stock.

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19.